BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012-2024. [PMID: 31727409 DOI: 10.1016/s0140-6736(19)32517-6] [Cited by in Crossref: 226] [Cited by in F6Publishing: 235] [Article Influence: 56.5] [Reference Citation Analysis]
Number Citing Articles
1 Lee E, Korf H, Vidal-Puig A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. J Hepatol 2023:S0168-8278(23)00077-6. [PMID: 36740049 DOI: 10.1016/j.jhep.2023.01.024] [Reference Citation Analysis]
2 Fromenty B, Roden M. Mitochondrial alterations in fatty liver diseases. J Hepatol 2023;78:415-29. [PMID: 36209983 DOI: 10.1016/j.jhep.2022.09.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Loomba R, Lawitz EJ, Frias JP, Ortiz-Lasanta G, Johansson L, Franey BB, Morrow L, Rosenstock M, Hartsfield CL, Chen CY, Tseng L, Charlton RW, Mansbach H, Margalit M. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol 2023;8:120-32. [PMID: 36521501 DOI: 10.1016/S2468-1253(22)00347-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lin S, Huang S, Deng Z, Zhang Y, Huang L, Wu Y, Lv S, Wang Z, Huang N, Wang L, Chen Z, Yu G, Yin W, Zhou Y, Fang Z. Discovery of a novel, liver-targeted thyroid hormone receptor-β agonist, CS271011, in the treatment of lipid metabolism disorders. Front Endocrinol (Lausanne) 2023;14:1109615. [PMID: 36742393 DOI: 10.3389/fendo.2023.1109615] [Reference Citation Analysis]
5 Torosian K, Lal E, Kavanaugh A, Loomba R, Ajmera V, Guma M. Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. Semin Arthritis Rheum 2023;59:152165. [PMID: 36716599 DOI: 10.1016/j.semarthrit.2023.152165] [Reference Citation Analysis]
6 Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne) 2022;13:1087260. [PMID: 36726464 DOI: 10.3389/fendo.2022.1087260] [Reference Citation Analysis]
7 Cernea S, Onișor D. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World J Gastroenterol 2023; 29(2): 286-309 [PMID: 36687124 DOI: 10.3748/wjg.v29.i2.286] [Reference Citation Analysis]
8 Akl MG, Widenmaier SB. Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma. Front Cell Dev Biol 2022;10:1089124. [PMID: 36712976 DOI: 10.3389/fcell.2022.1089124] [Reference Citation Analysis]
9 de Assis LVM, Demir M, Oster H. The role of the circadian clock in the development, progression, and treatment of non-alcoholic fatty liver disease. Acta Physiol (Oxf) 2023;:e13915. [PMID: 36599410 DOI: 10.1111/apha.13915] [Reference Citation Analysis]
10 Wolf P, Scherer T, Krebs M. Regulation of fat stores—endocrinological pathways. Visceral and Ectopic Fat 2023. [DOI: 10.1016/b978-0-12-822186-0.00018-3] [Reference Citation Analysis]
11 Li Y, Lei R, Lei H, Xiong Q, Xie F, Yao C, Feng P. Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Eur J Gastroenterol Hepatol 2023;35:1-14. [PMID: 36468565 DOI: 10.1097/MEG.0000000000002471] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wiering L, Tacke F. Treating inflammation to combat non-alcoholic fatty liver disease. J Endocrinol 2023;256:e220194. [PMID: 36259984 DOI: 10.1530/JOE-22-0194] [Reference Citation Analysis]
13 Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol 2023;29:77-98. [PMID: 36226471 DOI: 10.3350/cmh.2022.0237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Jirapinyo P, Zucker SD, Thompson CC. Regression of Hepatic Fibrosis Following Endoscopic Gastric Plication in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2022. [PMID: 36597405 DOI: 10.14309/ajg.0000000000002087] [Reference Citation Analysis]
15 Roehlen N, Saviano A, El Saghire H, Crouchet E, Nehme Z, Del Zompo F, Jühling F, Oudot MA, Durand SC, Duong FHT, Cherradi S, Gonzalez Motos V, Almeida N, Ponsolles C, Heydmann L, Ostyn T, Lallement A, Pessaux P, Felli E, Cavalli A, Sgrignani J, Thumann C, Koutsopoulos O, Fuchs BC, Hoshida Y, Hofmann M, Vyberg M, Viuff BM, Galsgaard ED, Elson G, Toso A, Meyer M, Iacone R, Schweighoffer T, Teixeira G, Moll S, De Vito C, Roskams T, Davidson I, Heide D, Heikenwälder M, Zeisel MB, Lupberger J, Mailly L, Schuster C, Baumert TF. A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity. Sci Transl Med 2022;14:eabj4221. [PMID: 36542691 DOI: 10.1126/scitranslmed.abj4221] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Chen JYS, Chua D, Lim CO, Ho WX, Tan NS. Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. Int J Mol Sci 2022;24. [PMID: 36613602 DOI: 10.3390/ijms24010158] [Reference Citation Analysis]
17 Liu Q, Li H, He W, Zhao Q, Huang C, Wang Q, Zheng Z, Zhang X, Shi X, Li X. Role of aerobic exercise in ameliorating NASH: Insights into the hepatic thyroid hormone signaling and circulating thyroid hormones. Front Endocrinol (Lausanne) 2022;13:1075986. [PMID: 36605939 DOI: 10.3389/fendo.2022.1075986] [Reference Citation Analysis]
18 Copur S, Yavuz F, Kanbay M. Thyroid hormone Beta receptor agonists for treatment of kidney disease: A promising agent? Eur J Clin Invest 2022;:e13939. [PMID: 36537819 DOI: 10.1111/eci.13939] [Reference Citation Analysis]
19 He W, Huang C, Wang L, Su W, Wang S, Huang P, Zhang X, Huang Y, Zhao Y, Lin M, Shi X, Li X. The correlation between triiodothyronine and the severity of liver fibrosis. BMC Endocr Disord 2022;22:313. [PMID: 36503486 DOI: 10.1186/s12902-022-01228-8] [Reference Citation Analysis]
20 Che W, Zhao M, Li X, Li C, Cho WC, Yu S. Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment. Front Endocrinol (Lausanne) 2022;13:1002916. [PMID: 36523601 DOI: 10.3389/fendo.2022.1002916] [Reference Citation Analysis]
21 Tay PWL, Ng CH, Lin SY, Chin YH, Xiao J, Lim WH, Lim SY, Fu CE, Chan KE, Quek J, Tan DJH, Chew N, Syn N, Keitoku T, Tamaki N, Siddiqui MS, Noureddin M, Muthiah M, Huang DQ, Loomba R. Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants. Am J Gastroenterol 2022. [PMID: 36191268 DOI: 10.14309/ajg.0000000000002042] [Reference Citation Analysis]
22 Hönes GS, Sivakumar RG, Hoppe C, König J, Führer D, Moeller LC. Cell-Specific Transport and Thyroid Hormone Receptor Isoform Selectivity Account for Hepatocyte-Targeted Thyromimetic Action of MGL-3196. Int J Mol Sci 2022;23. [PMID: 36430194 DOI: 10.3390/ijms232213714] [Reference Citation Analysis]
23 Fu Y, Zhou Y, Shen L, Li X, Zhang H, Cui Y, Zhang K, Li W, Chen W, Zhao S, Li Y, Ye W. Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.973366] [Reference Citation Analysis]
24 Zhang Y, Dalamaga M, Liu J. Targeting MRG15 for the treatment of nonalcoholic steatohepatitis. Metabolism Open 2022. [DOI: 10.1016/j.metop.2022.100217] [Reference Citation Analysis]
25 Brennan PN, Dillon JF, McCrimmon R. Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis. touchREV Endocrinol 2022;18:148-55. [PMID: 36694893 DOI: 10.17925/EE.2022.18.2.148] [Reference Citation Analysis]
26 Lonardo A, Mantovani A, Targher G, Baffy G. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications. IJMS 2022;23:13320. [DOI: 10.3390/ijms232113320] [Reference Citation Analysis]
27 Tian G, Luo Y, Lou B, Sui J, Qin X, Shen Y, Zhu X, Lu J. Screening, packing systematics, Hansen solubility parameters and desolvation of resmetirom (MGL-3196) solvates. Journal of Molecular Liquids 2022. [DOI: 10.1016/j.molliq.2022.120857] [Reference Citation Analysis]
28 Hatziagelaki E, Paschou SA, Schön M, Psaltopoulou T, Roden M. NAFLD and thyroid function: pathophysiological and therapeutic considerations. Trends Endocrinol Metab 2022;33:755-68. [PMID: 36171155 DOI: 10.1016/j.tem.2022.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Dufour JF, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, Tilg H, Wong VW, Zelber-Sagi S. Current therapies and new developments in NASH. Gut 2022;71:2123-34. [PMID: 35710299 DOI: 10.1136/gutjnl-2021-326874] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
30 Pai RK, Jairath V, Hogan M, Zou G, Adeyi OA, Anstee QM, Aqel BA, Behling C, Carey EJ, Clouston AD, Corey K, Feagan BG, Kleiner DE, Ma C, McFarlane SC, Noureddin M, Ratziu V, Valasek MA, Younossi ZM, Harrison SA, Loomba R. Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology 2022;76:1150-63. [PMID: 35332569 DOI: 10.1002/hep.32475] [Reference Citation Analysis]
31 Romero-gómez M. Non-alcoholic steatohepatitis. Medicina Clínica (English Edition) 2022;159:388-395. [DOI: 10.1016/j.medcle.2022.09.004] [Reference Citation Analysis]
32 Shen K, Singh AD, Modaresi Esfeh J, Wakim-Fleming J. Therapies for non-alcoholic fatty liver disease: A 2022 update. World J Hepatol 2022; 14(9): 1718-1729 [DOI: 10.4254/wjh.v14.i9.1718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Mandour MO, El-Hassan M, Elkomi RM, Oben JA. Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future? World J Hepatol 2022; 14(9): 1704-1717 [DOI: 10.4254/wjh.v14.i9.1704] [Reference Citation Analysis]
34 Suri J, Borja S, Lim JK. Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. World J Gastroenterol 2022; 28(35): 5129-5140 [DOI: 10.3748/wjg.v28.i35.5129] [Reference Citation Analysis]
35 Javanbakht M, Fishman J, Moloney E, Rydqvist P, Ansaripour A. Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis. PharmacoEconomics Open. [DOI: 10.1007/s41669-022-00370-2] [Reference Citation Analysis]
36 Romero-Gómez M. Non-alcoholic steatohepatitis. Med Clin (Barc) 2022:S0025-7753(22)00403-1. [PMID: 36075749 DOI: 10.1016/j.medcli.2022.06.017] [Reference Citation Analysis]
37 Badmus OO, Hillhouse SA, Anderson CD, Hinds TD, Stec DE. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clin Sci (Lond) 2022;136:1347-66. [PMID: 36148775 DOI: 10.1042/CS20220572] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
38 Basu R, Noureddin M, Clark JM. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers. Mayo Clin Proc 2022;97:1700-16. [PMID: 36058582 DOI: 10.1016/j.mayocp.2022.04.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Zunica ERM, Heintz EC, Axelrod CL, Kirwan JP. Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:4051. [PMID: 36011044 DOI: 10.3390/cancers14164051] [Reference Citation Analysis]
40 Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022;7:287. [PMID: 35963848 DOI: 10.1038/s41392-022-01119-3] [Reference Citation Analysis]
41 Wirth EK, Puengel T, Spranger J, Tacke F. Thyroid hormones as a disease modifier and therapeutic target in non-alcoholic steatohepatitis. Expert Review of Endocrinology & Metabolism. [DOI: 10.1080/17446651.2022.2110864] [Reference Citation Analysis]
42 Marschner RA, Arenhardt F, Ribeiro RT, Wajner SM. Influence of Altered Thyroid Hormone Mechanisms in the Progression of Metabolic Dysfunction Associated with Fatty Liver Disease (MAFLD): A Systematic Review. Metabolites 2022;12:675. [DOI: 10.3390/metabo12080675] [Reference Citation Analysis]
43 Wang Z, Ye M, Zhang XJ, Zhang P, Cai J, Li H, She ZG. Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. Atherosclerosis 2022;355:30-44. [PMID: 35872444 DOI: 10.1016/j.atherosclerosis.2022.07.010] [Reference Citation Analysis]
44 Teng T, Qiu S, Zhao Y, Zhao S, Sun D, Hou L, Li Y, Zhou K, Yu X, Yang C, Li Y. Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:7841. [PMID: 35887189 DOI: 10.3390/ijms23147841] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Hassanein T, Tai D, Liu C, Box TD, Tong MJ, Rossaro L, Pozza R, Glenn JS, Cheung R, Hemaidan A, He Y, Behling C, Hu X, Makhlouf H, Fan H, Ren Y, Khim Chng EL, Liu P, Vierling JM. Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-11. [DOI: 10.1155/2022/4494099] [Reference Citation Analysis]
46 Iwaki M, Kessoku T, Tanaka K, Ozaki A, Kasai Y, Yamamoto A, Takahashi K, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Yoneda M, Kobayashi N, Saito S, Nakajima A. Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study. BMJ Open 2022;12:e060335. [PMID: 35820743 DOI: 10.1136/bmjopen-2021-060335] [Reference Citation Analysis]
47 Yan M, Man S, Ma L, Gao W. Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. Metabolism 2022;134:155264. [PMID: 35810782 DOI: 10.1016/j.metabol.2022.155264] [Reference Citation Analysis]
48 Urva S, Quinlan T, Landry J, Ma X, Martin JA, Benson CT. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet 2022;61:1057-67. [PMID: 35674880 DOI: 10.1007/s40262-022-01140-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Stine JG, Schreibman IR, Faust AJ, Dahmus J, Stern B, Soriano C, Rivas G, Hummer B, Kimball SR, Geyer NR, Chinchilli VM, Loomba R, Schmitz K, Sciamanna C. NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH. Hepatology 2022;76:172-85. [PMID: 34890063 DOI: 10.1002/hep.32274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
50 Valenzuela-Vallejo L, Mantzoros CS. Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD). Metabolism 2022;:155246. [PMID: 35780909 DOI: 10.1016/j.metabol.2022.155246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Perra A, Plateroti M. Editorial: Targeting Thyroid Hormone-Dependent Pathways in Proliferative and Degenerative Disorders. Front Med (Lausanne) 2022;9:944769. [PMID: 35755068 DOI: 10.3389/fmed.2022.944769] [Reference Citation Analysis]
52 Vijayakumar A, Okesli-Armlovich A, Wang T, Olson I, Seung M, Kusam S, Hollenback D, Mahadevan S, Marchand B, Toteva M, Breckenridge DG, Trevaskis JL, Bates J. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. Hepatol Commun 2022. [PMID: 35735253 DOI: 10.1002/hep4.2011] [Reference Citation Analysis]
53 Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, Chen CY, Zuckerman E, Ravussin E, Charatcharoenwitthaya P, Cheng PN, Katchman H, Klein S, Ben-Ari Z, Mendonza AE, Zhang Y, Martic M, Ma S, Kao S, Tanner S, Pachori A, Badman MK, He Y, Ukomadu C, Sicard E. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med 2022. [PMID: 35725922 DOI: 10.1038/s41591-022-01861-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Zhou J, Tripathi M, Ho JP, Widjaja AA, Shekeran SG, Camat MD, James A, Wu Y, Ching J, Kovalik JP, Lim KH, Cook SA, Bay BH, Singh BK, Yen PM. Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis. Thyroid 2022;32:725-38. [PMID: 35317606 DOI: 10.1089/thy.2021.0621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
55 Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol 2022;76:1263-78. [PMID: 35589249 DOI: 10.1016/j.jhep.2022.04.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
56 Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. The Lancet Diabetes & Endocrinology 2022;10:393-406. [DOI: 10.1016/s2213-8587(22)00070-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 17.0] [Reference Citation Analysis]
57 Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine 2022;80:104069. [PMID: 35605429 DOI: 10.1016/j.ebiom.2022.104069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Ng CH, Xiao J, Lim WH, Chin YH, Yong JN, Tan DJH, Tay P, Syn N, Foo R, Chan M, Chew N, Tan EX, Huang DQ, Dan YY, Tamaki N, Siddiqui MS, Sanyal AJ, Loomba R, Noureddin M, Muthiah MD. Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. Hepatology 2022;75:1647-61. [PMID: 34990037 DOI: 10.1002/hep.32315] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
59 Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. Clin Gastroenterol Hepatol 2022;20:1354-1361.e7. [PMID: 34329774 DOI: 10.1016/j.cgh.2021.07.039] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
60 Spiers J, Brindley JH, Li W, Alazawi W. What's new in non-alcoholic fatty liver disease? Frontline Gastroenterol 2022;13:e102-8. [PMID: 35812024 DOI: 10.1136/flgastro-2022-102122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
61 Liao C, Huang P, Chien H, Lin T, Yeh C, Lin K. Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease. Biomedicines 2022;10:1232. [DOI: 10.3390/biomedicines10061232] [Reference Citation Analysis]
62 Cheng H, Wang X, Zhi Y, Liu B, Liu N, Li M, Mu Y. A Pyridazinone Compound for Effectively Treating Non-alcoholic Steatohepatitis by Targeting THRβ. Front Chem 2022;10:888587. [DOI: 10.3389/fchem.2022.888587] [Reference Citation Analysis]
63 Branković M, Jovanović I, Dukić M, Radonjić T, Oprić S, Klašnja S, Zdravković M. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. Int J Mol Sci 2022;23:5146. [PMID: 35563534 DOI: 10.3390/ijms23095146] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
64 Li Q, Yao B, Zhao S, Lu Z, Zhang Y, Xiang Q, Wu X, Yu H, Zhang C, Li J, Zhuang X, Wu D, Li Y, Xu Y. Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist. J Med Chem 2022. [PMID: 35507418 DOI: 10.1021/acs.jmedchem.2c00144] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Curr Atheroscler Rep 2022. [PMID: 35507280 DOI: 10.1007/s11883-022-01027-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
66 Marjot T, Ray DW, Tomlinson JW. Is it time for chronopharmacology in NASH? J Hepatol 2022;76:1215-24. [PMID: 35066087 DOI: 10.1016/j.jhep.2021.12.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
67 Ng CH, Muthiah MD, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Tan DJH, Yong JN, Pan XH, Koh JWH, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. Aliment Pharmacol Ther 2022;55:1076-87. [PMID: 35285529 DOI: 10.1111/apt.16808] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
68 Shi YW, Fan JG. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1191-9. [PMID: 34907360 DOI: 10.1038/s41401-021-00822-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
69 Yang YY, Xie L, Zhang NP, Zhou D, Liu TT, Wu J. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1180-90. [PMID: 35190696 DOI: 10.1038/s41401-022-00860-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
70 Brunt EM, Clouston AD, Goodman Z, Guy C, Kleiner DE, Lackner C, Tiniakos DG, Wee A, Yeh M, Leow WQ, Chng E, Ren Y, Boon Bee GG, Powell EE, Rinella M, Sanyal AJ, Neuschwander-Tetri B, Younossi Z, Charlton M, Ratziu V, Harrison SA, Tai D, Anstee QM. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol 2022;76:1030-41. [PMID: 35090960 DOI: 10.1016/j.jhep.2022.01.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
71 Pourvali K, Shimi G, Ghorbani A, Shakery A, Shirazi FH, Zand H. Selective thyroid hormone receptor beta agonist, GC-1, is capable to reduce growth of colorectal tumor in syngeneic mouse models. J Recept Signal Transduct Res 2022;:1-8. [PMID: 35473566 DOI: 10.1080/10799893.2022.2032748] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Hovingh GK, Klausen IC, Heggen E, McCarty K, Zhou R, Isaac BF, Taub R, Langslet G, Kastelein JJP. Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia. J Am Coll Cardiol 2022;79:1220-2. [PMID: 35331419 DOI: 10.1016/j.jacc.2022.01.023] [Reference Citation Analysis]
73 Von-hafe M, Borges-canha M, Vale C, Leite AR, Sérgio Neves J, Carvalho D, Leite-moreira A. Nonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review. Metabolites 2022;12:298. [DOI: 10.3390/metabo12040298] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
74 Kemas AM, Youhanna S, Lauschke VM. Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development. Expert Review of Precision Medicine and Drug Development 2022;7:39-49. [DOI: 10.1080/23808993.2022.2053285] [Reference Citation Analysis]
75 Rowe IA, Parker R. The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained. Clin Gastroenterol Hepatol 2022;20:e564-72. [PMID: 34091047 DOI: 10.1016/j.cgh.2021.05.059] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
76 Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol 2022;76:536-48. [PMID: 34793868 DOI: 10.1016/j.jhep.2021.10.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
77 Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol 2022;76:506-17. [PMID: 34740705 DOI: 10.1016/j.jhep.2021.10.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
78 Uehara K, Sostre-Colón J, Gavin M, Santoleri D, Leonard KA, Jacobs RL, Titchenell PM. Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. Cell Mol Gastroenterol Hepatol 2022;13:1625-47. [PMID: 35240344 DOI: 10.1016/j.jcmgh.2022.02.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
79 Zhou Z, Wang H, Zhang X, Song M, Yao S, Jiang P, Liu D, Wang Z, Lv H, Li R, Hong Y, Dai J, Hu Y, Zhao G. Defective autophagy contributes to endometrial epithelial-mesenchymal transition in intrauterine adhesions. Autophagy 2022;:1-16. [PMID: 35196191 DOI: 10.1080/15548627.2022.2038994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Patikorn C, Veettil SK, Phisalprapa P, Pham T, Kowdley KV, Chaiyakunapruk N. Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. Ann Hepatol 2021;24:100315. [PMID: 33515800 DOI: 10.1016/j.aohep.2021.100315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
81 Sebastiani G, Patel K, Ratziu V, Feld JJ, Neuschwander-tetri BA, Pinzani M, Petta S, Berzigotti A, Metrakos P, Shoukry N, Brunt EM, Tang A, Cobbold JF, Ekoe J, Seto K, Ghali P, Chevalier S, Anstee QM, Watson H, Bajaj H, Stone J, Swain MG, Ramji A. Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). CanLivJ 2022;5:61-90. [DOI: 10.3138/canlivj-2021-0030] [Reference Citation Analysis]
82 Lewis GF, Hegele RA. Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. The Lancet Diabetes & Endocrinology 2022;10:142-8. [DOI: 10.1016/s2213-8587(21)00284-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
83 Aggarwal P, Noureddin M, Harrison S, Jeannin S, Alkhouri N. Nonalcoholic steatohepatitis (NASH) cirrhosis: A snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2032640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Zhao M, Xie H, Shan H, Zheng Z, Li G, Li M, Hong L. Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:1102. [PMID: 35163026 DOI: 10.3390/ijms23031102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
85 F. Lange N, Dufour J. Spezifische Therapie – neue Medikamente. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_21] [Reference Citation Analysis]
86 Albhaisi S, Sanyal AJ. Pharmacology of NASH. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00121-3] [Reference Citation Analysis]
87 Imajo K, Honda Y, Yoneda M, Saito S, Nakajima A. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. Jpn J Med Ultrasonics 2022;49:411-425. [DOI: 10.3179/jjmu.jjmu.r.203] [Reference Citation Analysis]
88 Georgescu CE. Polycystic ovary syndrome and nonalcoholic fatty liver disease. Polycystic Ovary Syndrome 2022. [DOI: 10.1016/b978-0-12-823045-9.00007-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Padole P, Arora A, Sharma P, Chand P, Verma N, Kumar A. Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients. J Clin Exp Hepatol 2022;12:435-9. [PMID: 35535066 DOI: 10.1016/j.jceh.2021.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Patel V, Joharapurkar A, Kshirsagar S, Patel M, Patel H, Savsani H, Jain M. Microsomal triglyceride transfer protein inhibitor lomitapide-induced liver toxicity is ameliorated by Triiodothyronine treatment following improved bile homeostasis and β-oxidation. Toxicol Appl Pharmacol 2022;434:115825. [PMID: 34902352 DOI: 10.1016/j.taap.2021.115825] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
91 Lee D, Trinh TA, Shin M, Kang KS. Adipose tissue. Recent Advancements in Microbial Diversity 2022. [DOI: 10.1016/b978-0-12-822368-0.00009-8] [Reference Citation Analysis]
92 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 28.0] [Reference Citation Analysis]
93 Ampuero J, Gallego-Durán R, Maya-Miles D, Montero R, Gato S, Rojas Á, Gil A, Muñoz R, Romero-Gómez M. Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. J Gastroenterol 2022;57:357-71. [PMID: 35325295 DOI: 10.1007/s00535-022-01860-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
94 Prasoppokakorn T, Pitisuttithum P, Treeprasertsuk S. Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). J Clin Transl Hepatol 2021;9:939-46. [PMID: 34966657 DOI: 10.14218/JCTH.2021.00189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
95 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
96 Yang M, Khoukaz L, Qi X, Kimchi ET, Staveley-O'Carroll KF, Li G. Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment. Biomedicines 2021;9:1893. [PMID: 34944709 DOI: 10.3390/biomedicines9121893] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
97 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
98 Caddeo A, Kowalik MA, Serra M, Runfola M, Bacci A, Rapposelli S, Columbano A, Perra A. TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD. Int J Mol Sci 2021;22:13105. [PMID: 34884910 DOI: 10.3390/ijms222313105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
99 Mavromati M, Jornayvaz FR. Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD. Int J Mol Sci 2021;22:12797. [PMID: 34884625 DOI: 10.3390/ijms222312797] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
100 Satiya J, Snyder HS, Singh SP, Satapathy SK. Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. Transl Gastroenterol Hepatol 2021;6:60. [PMID: 34805582 DOI: 10.21037/tgh-20-247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
101 Mendoza A, Tang C, Choi J, Acuña M, Logan M, Martin AG, Al-Sowaimel L, Desai BN, Tenen DE, Jacobs C, Lyubetskaya A, Fu Y, Liu H, Tsai L, Cohen DE, Forrest D, Wilson AA, Hollenberg AN. Thyroid hormone signaling promotes hepatic lipogenesis through the transcription factor ChREBP. Sci Signal 2021;14:eabh3839. [PMID: 34784250 DOI: 10.1126/scisignal.abh3839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
103 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Cited by in Crossref: 42] [Cited by in F6Publishing: 56] [Article Influence: 21.0] [Reference Citation Analysis]
104 Steinman JB, Salomao MA, Pajvani UB. Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes. Liver Int 2021;41:2534-46. [PMID: 34328687 DOI: 10.1111/liv.15025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
105 Muthiah MD, Ng CH, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Hao Tan DJ, Yong JN, Pan X, Heng Koh JW, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Analysis of Mechanistic Pathways in the Treatment of Non-Alcoholic Steatohepatitis. Evidence from a Bayesian Network Meta-Analysis.. [DOI: 10.1101/2021.10.22.21265361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Majumdar A, Verbeek J, Tsochatzis EA. Non-alcoholic fatty liver disease: Current therapeutic options. Curr Opin Pharmacol 2021;61:98-105. [PMID: 34688168 DOI: 10.1016/j.coph.2021.09.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
107 Videla LA, Valenzuela R. Perspectives in liver redox imbalance: Toxicological and pharmacological aspects underlying iron overloading, nonalcoholic fatty liver disease, and thyroid hormone action. Biofactors 2021. [PMID: 34687092 DOI: 10.1002/biof.1797] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
108 Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, Yao Y, Ye T. Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. Front Cell Dev Biol 2021;9:730176. [PMID: 34621747 DOI: 10.3389/fcell.2021.730176] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis]
109 Yang M, Geng CA, Liu X, Guan M. Lipid Disorders in NAFLD and Chronic Kidney Disease. Biomedicines 2021;9:1405. [PMID: 34680522 DOI: 10.3390/biomedicines9101405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
110 Kanorskii SG. Non-alcoholic fatty liver disease: modern approaches to diagnosis and treatment. jour 2021;2:18-29. [DOI: 10.21886/2712-8156-2021-2-3-18-29] [Reference Citation Analysis]
111 Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S, Sanyal AJ; ARREST investigator study group. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 2021;27:1825-35. [PMID: 34621052 DOI: 10.1038/s41591-021-01495-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 18.0] [Reference Citation Analysis]
112 Czarnecka K, Czarnecka P, Tronina O, Bączkowska T, Durlik M. Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation. Immun Inflamm Dis 2021. [PMID: 34598315 DOI: 10.1002/iid3.538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther 2021;54:880-9. [PMID: 34435378 DOI: 10.1111/apt.16583] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
114 Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. Drug Des Devel Ther 2021;15:3997-4009. [PMID: 34588764 DOI: 10.2147/DDDT.S315724] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
115 Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Méndez-Sánchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Ann Hepatol 2020;19:674-90. [PMID: 33031970 DOI: 10.1016/j.aohep.2020.09.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 21.5] [Reference Citation Analysis]
116 Kuchay MS, Martínez-Montoro JI, Choudhary NS, Fernández-García JC, Ramos-Molina B. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines 2021;9:1346. [PMID: 34680463 DOI: 10.3390/biomedicines9101346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
117 Cusi K, Alkhouri N, Harrison SA, Fouqueray P, Moller DE, Hallakou-Bozec S, Bolze S, Grouin JM, Jeannin Megnien S, Dubourg J, Ratziu V. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Gastroenterol Hepatol 2021;6:889-902. [PMID: 34560015 DOI: 10.1016/S2468-1253(21)00300-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
118 Alkhouri N, Tincopa M, Loomba R, Harrison SA. What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? Hepatol Commun 2021;5:1810-23. [PMID: 34499435 DOI: 10.1002/hep4.1814] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
119 Van Gaal LF, Mertens J, Francque S, De Block C. Therapeutic approaches for non-alcoholic steatohepatitis. Ther Adv Endocrinol Metab 2021;12:20420188211034300. [PMID: 34497708 DOI: 10.1177/20420188211034300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
120 Erhardtsen E, Rasmussen DGK, Frederiksen P, Leeming DJ, Shevell D, Gluud LL, Karsdal MA, Aithal GP, Schattenberg JM. Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis. JHEP Rep 2021;3:100317. [PMID: 34466796 DOI: 10.1016/j.jhepr.2021.100317] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
121 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 160] [Cited by in F6Publishing: 153] [Article Influence: 80.0] [Reference Citation Analysis]
122 Ratziu V. Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. Clin Liver Dis (Hoboken) 2021;17:398-400. [PMID: 34386202 DOI: 10.1002/cld.1076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, Trapani S, Floreani A, Marra F, Brunetto MR, Taliani G, Villa E; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 2021;41:1713-33. [PMID: 33982400 DOI: 10.1111/liv.14943] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
124 Harrison SA, Bashir MR, Lee KJ, Shim-Lopez J, Lee J, Wagner B, Smith ND, Chen HC, Lawitz EJ. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. J Hepatol 2021;75:25-33. [PMID: 33581174 DOI: 10.1016/j.jhep.2021.01.047] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 17.5] [Reference Citation Analysis]
125 Martínez-Escudé A, Pera G, Costa-Garrido A, Rodríguez L, Arteaga I, Expósito-Martínez C, Torán-Monserrat P, Caballería L. TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population. J Clin Med 2021;10:2907. [PMID: 34209831 DOI: 10.3390/jcm10132907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
126 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95. [PMID: 34131333 DOI: 10.1038/s41574-021-00507-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 23.5] [Reference Citation Analysis]
127 Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
128 Liebe R, Esposito I, Bock HH, Vom Dahl S, Stindt J, Baumann U, Luedde T, Keitel V. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol 2021;74:1455-71. [PMID: 33577920 DOI: 10.1016/j.jhep.2021.01.045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
129 Davison BA, Edwards C, Loomba R, Harrison SA, Cotter G, Alkhouri N, Koch GG, Dittrich HC. Noninvasive measure of treatment response in non-alcoholic steatohepatitis: Insights from EMMINENCE and meta-analysis. JGH Open 2021;5:740-9. [PMID: 34263067 DOI: 10.1002/jgh3.12575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
130 Albhaisi SAM, Sanyal AJ. New drugs for NASH. Liver Int 2021;41 Suppl 1:112-8. [PMID: 34155794 DOI: 10.1111/liv.14844] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
131 Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 51.5] [Reference Citation Analysis]
132 Du J, Chai S, Zhao X, Sun J, Zhang X, Huo L. Association Between Thyroid Hormone Levels and Advanced Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:2399-406. [PMID: 34079318 DOI: 10.2147/DMSO.S313503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
133 Bruinstroop E, Zhou J, Tripathi M, Yau WW, Boelen A, Singh BK, Yen PM. Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression.. [DOI: 10.1101/2021.05.13.443791] [Reference Citation Analysis]
134 Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther 2021;38:2130-58. [PMID: 33829368 DOI: 10.1007/s12325-021-01690-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
135 Moran C, McEniery CM, Schoenmakers N, Mitchell C, Sleigh A, Watson L, Lyons G, Burling K, Barker P, Chatterjee K. Dyslipidemia, Insulin Resistance, Ectopic Lipid Accumulation, and Vascular Function in Resistance to Thyroid Hormone β. J Clin Endocrinol Metab 2021;106:e2005-14. [PMID: 33524107 DOI: 10.1210/clinem/dgab002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
136 Gastaldelli A, Stefan N, Häring HU. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia 2021;64:1461-79. [PMID: 33877366 DOI: 10.1007/s00125-021-05442-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
137 D'Ambrosio R, Campi I, Maggioni M, Perbellini R, Giammona E, Stucchi R, Borghi M, Degasperi E, De Silvestri A, Persani L, Fugazzola L, Lampertico P. The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD). PLoS One 2021;16:e0249614. [PMID: 33822817 DOI: 10.1371/journal.pone.0249614] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
138 Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med 2021;9:729. [PMID: 33987427 DOI: 10.21037/atm-20-4354] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 14.0] [Reference Citation Analysis]
139 Roca-Fernández A, Dennis A, Nicholls R, McGonigle J, Kelly M, Banerjee R, Banerjee A, Sanyal AJ. Hepatic Steatosis, Rather Than Underlying Obesity, Increases the Risk of Infection and Hospitalization for COVID-19. Front Med (Lausanne) 2021;8:636637. [PMID: 33855033 DOI: 10.3389/fmed.2021.636637] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
140 Huisman TM, Dieterich DT, Friedman SL. Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update. J Exp Pharmacol 2021;13:329-38. [PMID: 33776490 DOI: 10.2147/JEP.S265286] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
141 Rupcic Rubin V, Bojanic K, Smolic M, Rubin J, Tabll A, Smolic R. An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents. J Clin Transl Hepatol 2021;9:60-70. [PMID: 33604256 DOI: 10.14218/JCTH.2020.00040] [Reference Citation Analysis]
142 Rupcic Rubin V, Bojanic K, Smolic M, Rubin J, Tabll A, Smolic R. An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents. J Clin Transl Hepatol 2021;9:60-70. [PMID: 33604256 DOI: 10.14218/JCTH.2020.00040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021;22:2350. [PMID: 33652942 DOI: 10.3390/ijms22052350] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 18.5] [Reference Citation Analysis]
144 Chaves C, Bruinstroop E, Refetoff S, Yen PM, Anselmo J. Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta. Thyroid 2021;31:1127-34. [PMID: 33353459 DOI: 10.1089/thy.2020.0651] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
145 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 24.0] [Reference Citation Analysis]
146 Shen B, Lu LG. Efficacy and safety of drugs for nonalcoholic steatohepatitis. J Dig Dis 2021;22:72-82. [PMID: 33385317 DOI: 10.1111/1751-2980.12967] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
147 Dennis A, Kelly MD, Fernandes C, Mouchti S, Fallowfield JA, Hirschfield G, Pavlides M, Harrison S, Chakravarthy MV, Banerjee R, Sanyal A. Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2020;11:575843. [PMID: 33584535 DOI: 10.3389/fendo.2020.575843] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
148 Palmieri B, Corazzari V, Panariello Brasile DG, Sangiovanni V, VadalÀ M. Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration. Minerva Gastroenterol Dietol 2020;66:307-20. [PMID: 33443240 DOI: 10.23736/S1121-421X.20.02738-5] [Reference Citation Analysis]
149 Harrison SA, Bashir M, Moussa SE, McCarty K, Pablo Frias J, Taub R, Alkhouri N. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. Hepatol Commun 2021;5:573-88. [PMID: 33860116 DOI: 10.1002/hep4.1657] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
150 Krolevets T, Livzan V. Non-alcoholic fatty liver disease: digest 2021. Dok gastroenterol 2021;10:27. [DOI: 10.17116/dokgastro20211002127] [Reference Citation Analysis]
151 Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP, Younes Z, Trotter JF, Gunn NT, Moussa SE, Kohli A, Nelson K, Gottwald M, Chang WCG, Yan AZ, DePaoli AM, Ling L, Lieu HD. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Gastroenterology 2021;160:219-231.e1. [PMID: 32781086 DOI: 10.1053/j.gastro.2020.08.004] [Cited by in Crossref: 103] [Cited by in F6Publishing: 102] [Article Influence: 51.5] [Reference Citation Analysis]
152 Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed) 2021;26:206-37. [PMID: 33049668 DOI: 10.2741/4892] [Cited by in Crossref: 23] [Cited by in F6Publishing: 32] [Article Influence: 11.5] [Reference Citation Analysis]
153 Finan B, Parlee SD, Yang B. Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. Mol Metab 2021;46:101153. [PMID: 33359400 DOI: 10.1016/j.molmet.2020.101153] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
154 Tillman EJ, Rolph T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front Endocrinol (Lausanne) 2020;11:601290. [PMID: 33381084 DOI: 10.3389/fendo.2020.601290] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 15.7] [Reference Citation Analysis]
155 Luong XG, Stevens SK, Jekle A, Lin TI, Gupta K, Misner D, Chanda S, Mukherjee S, Williams C, Stoycheva A, Blatt LM, Beigelman LN, Symons JA, Raboisson P, McGowan D, Vandyck K, Deval J. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). PLoS One 2020;15:e0240338. [PMID: 33306682 DOI: 10.1371/journal.pone.0240338] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
156 Odagiri N, Matsubara T, Sato-Matsubara M, Fujii H, Enomoto M, Kawada N. Anti-fibrotic treatments for chronic liver diseases: The present and the future. Clin Mol Hepatol 2021;27:413-24. [PMID: 33317250 DOI: 10.3350/cmh.2020.0187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
157 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
158 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91. [PMID: 33268887 DOI: 10.1038/s41423-020-00579-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
159 Horn CL, Ta AC, Gunn NT. Current and Emerging Treatments for Non-alcoholic Steatohepatitis. Curr Hepatology Rep 2020;19:391-401. [DOI: 10.1007/s11901-020-00540-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
160 Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L, Hrabar D, Smircic Duvnjak L. New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis. J Clin Transl Hepatol 2021;9:51-9. [PMID: 33604255 DOI: 10.14218/JCTH.2020.00057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
161 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 12.7] [Reference Citation Analysis]
162 Xiao Y, Kim M, Lazar MA. Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease. Mol Metab 2021;50:101119. [PMID: 33220489 DOI: 10.1016/j.molmet.2020.101119] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
163 Gauthier BR, Sola-García A, Cáliz-Molina MÁ, Lorenzo PI, Cobo-Vuilleumier N, Capilla-González V, Martin-Montalvo A. Thyroid hormones in diabetes, cancer, and aging. Aging Cell 2020;19:e13260. [PMID: 33048427 DOI: 10.1111/acel.13260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
164 Stokman G, van den Hoek AM, Denker Thorbekk D, Pieterman EJ, Skovgård Veidal S, Basta B, Iruarrizaga-Lejarreta M, van der Hoorn JW, Verschuren L, Berbée JFP, Rensen PCN, Skjaeret T, Alonso C, Feigh M, Kastelein JJP, Friedman SL, Princen HMG, Fraser DA. Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver Int 2020;40:2860-76. [PMID: 32841505 DOI: 10.1111/liv.14643] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
165 Mukherjee S. Advances in the treatment of nonalcoholic steatohepatitis. World J Pharmacol 2020; 9(1): 1-12 [DOI: 10.5497/wjp.v9.i1.1] [Reference Citation Analysis]
166 Borges-Canha M, Neves JS, Mendonça F, Silva MM, Costa C, Cabral PM, Guerreiro V, Lourenço R, Meira P, Salazar D, Ferreira MJ, Pedro J, Leite A, Von-Hafe M, Vale C, Viana S, Sande A, Belo S, Lau E, Freitas P, Carvalho D. Thyroid Function and the Risk of Non-Alcoholic Fatty Liver Disease in Morbid Obesity. Front Endocrinol (Lausanne) 2020;11:572128. [PMID: 33193088 DOI: 10.3389/fendo.2020.572128] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
167 Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44:640-657. [PMID: 33115209 DOI: 10.4093/dmj.2020.0115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
168 Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab 2020;42:101092. [PMID: 33010471 DOI: 10.1016/j.molmet.2020.101092] [Cited by in Crossref: 60] [Cited by in F6Publishing: 76] [Article Influence: 20.0] [Reference Citation Analysis]
169 Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-84. [PMID: 32381514 DOI: 10.1136/gutjnl-2019-319104] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 26.3] [Reference Citation Analysis]
170 Loomba R, Neuschwander-Tetri BA, Sanyal A, Chalasani N, Diehl AM, Terrault N, Kowdley K, Dasarathy S, Kleiner D, Behling C, Lavine J, Van Natta M, Middleton M, Tonascia J, Sirlin C; NASH Clinical Research Network. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. Hepatology 2020;72:1219-29. [PMID: 31965579 DOI: 10.1002/hep.31121] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 16.7] [Reference Citation Analysis]
171 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 176] [Cited by in F6Publishing: 199] [Article Influence: 58.7] [Reference Citation Analysis]
172 Kizivat T, Maric I, Mudri D, Curcic IB, Primorac D, Smolic M. Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications. J Clin Transl Hepatol 2020;8:347-53. [PMID: 33083258 DOI: 10.14218/JCTH.2020.00027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
173 Luong XG, Stevens SK, Jekle A, Lin T, Gupta K, Misner D, Chanda S, Mukherjee S, Williams C, Stoycheva A, Blatt LM, Beigelman LN, Symons JA, Raboisson P, Mcgowan D, Vandyck K, Deval J. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).. [DOI: 10.1101/2020.09.25.312934] [Reference Citation Analysis]
174 Kim YS, Kim SG. Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases. Clin Mol Hepatol 2020;26:715-27. [PMID: 32951410 DOI: 10.3350/cmh.2020.0173] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
175 Aggarwal P, Singh T, Alkhouri N. Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root. Curr Hepatology Rep 2020;19:302-314. [DOI: 10.1007/s11901-020-00533-x] [Reference Citation Analysis]
176 Tanase DM, Gosav EM, Neculae E, Costea CF, Ciocoiu M, Hurjui LL, Tarniceriu CC, Floria M. Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options. Int J Mol Sci 2020;21:E5927. [PMID: 32824723 DOI: 10.3390/ijms21165927] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
177 Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. Int J Mol Sci 2020;21:E5820. [PMID: 32823659 DOI: 10.3390/ijms21165820] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
178 Sinha RA, Bruinstroop E, Singh BK, Yen PM. Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis? Hepatology 2020;72:770-1. [PMID: 32104916 DOI: 10.1002/hep.31204] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
179 Ritter MJ, Amano I, Hollenberg AN. Thyroid Hormone Signaling and the Liver. Hepatology 2020;72:742-52. [PMID: 32343421 DOI: 10.1002/hep.31296] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 15.3] [Reference Citation Analysis]
180 Connelly MA, Velez Rivera J, Guyton JR, Siddiqui MS, Sanyal AJ. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2020;52:619-36. [PMID: 32638417 DOI: 10.1111/apt.15935] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
181 Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, Atkin SL, Mantzoros CS, Jamialahmadi T, Sahebkar A. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Mol Metab 2021;50:101049. [PMID: 32673798 DOI: 10.1016/j.molmet.2020.101049] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
182 Saponaro F, Sestito S, Runfola M, Rapposelli S, Chiellini G. Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders. Front Med (Lausanne) 2020;7:331. [PMID: 32733906 DOI: 10.3389/fmed.2020.00331] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
183 Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 2020;9:E1638. [PMID: 32650421 DOI: 10.3390/cells9071638] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
184 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 15.3] [Reference Citation Analysis]
185 Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol 2020;6:9. [PMID: 32518675 DOI: 10.1186/s40842-020-00097-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
186 Gadiparthi C, Spatz M, Greenberg S, Iqbal U, Kanna S, Satapathy SK, Broder A, Ahmed A. NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States. J Clin Transl Hepatol. 2020;8:215-221. [PMID: 32832402 DOI: 10.14218/jcth.2020.00014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
187 Long MT, Gandhi S, Loomba R. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism 2020;111S:154259. [PMID: 32387227 DOI: 10.1016/j.metabol.2020.154259] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
188 Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology 2020;158:1984-1998.e3. [PMID: 32061596 DOI: 10.1053/j.gastro.2020.01.051] [Cited by in Crossref: 87] [Cited by in F6Publishing: 83] [Article Influence: 29.0] [Reference Citation Analysis]
189 Perra A, Kowalik MA, Cabras L, Runfola M, Sestito S, Migliore C, Giordano S, Chiellini G, Rapposelli S, Columbano A. Potential role of two novel agonists of thyroid hormone receptor-β on liver regeneration. Cell Prolif 2020;53:e12808. [PMID: 32347601 DOI: 10.1111/cpr.12808] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
190 Zucchi R. Thyroid Hormone Analogues: An Update. Thyroid 2020;30:1099-105. [PMID: 32098589 DOI: 10.1089/thy.2020.0071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
191 Overi D, Carpino G, Franchitto A, Onori P, Gaudio E. Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis. Cells 2020;9:E590. [PMID: 32131439 DOI: 10.3390/cells9030590] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
192 Wong VW. Predicting NASH response with liver fat: Are we back to square one? J Hepatol 2020;72:386-8. [PMID: 31813574 DOI: 10.1016/j.jhep.2019.10.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
193 Noureddin N, Schattenberg JM, Alkhouri N, Noureddin M. Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass? Hepatol Commun 2020;4:141-4. [PMID: 32025600 DOI: 10.1002/hep4.1473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
194 Elhence A, Shalimar. Treatment of non-alcoholic fatty liver disease - Current perspectives. Indian J Gastroenterol 2020;39:22-31. [PMID: 32152902 DOI: 10.1007/s12664-020-01021-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
195 Cardoso AC, de Figueiredo-Mendes C, A Villela-Nogueira C, Sanyal AJ. New drugs for non-alcoholic steatohepatitis. Liver Int 2020;40 Suppl 1:96-101. [PMID: 32077615 DOI: 10.1111/liv.14354] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
196 Wai JW, Fu C, Wong VW. Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. J Gastroenterol 2020;55:731-41. [PMID: 32451628 DOI: 10.1007/s00535-020-01686-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
197 Ten Hove M, Pater L, Storm G, Weiskirchen S, Weiskirchen R, Lammers T, Bansal R. The hepatic lipidome: From basic science to clinical translation. Adv Drug Deliv Rev 2020;159:180-97. [PMID: 32615143 DOI: 10.1016/j.addr.2020.06.027] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]